Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous COVID-19 Vaccination ChAdOx-1S Followed by BNT162b2
DRKS00025271Phase 4Recruiting
- Sponsor
- Regensburg University Medical Center
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of ChAdOx1 nCoV-19, tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Regensburg University Medical Center. Started May 2021; status: recruiting.
02
Drugs
ChAdOx1 nCoV-19tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on DRKS00025271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00025271.